Company intelligence / Profile preview

Zocular

Ownership: Private
Employees: ~30
Development stage: Other

Overview

Zocular has developed several commercial eye care products using its proprietary Zokrex platform, which leverages activated okra-based polysaccharides to address ocular surface inflammation and biofilm. Clinical results for its ZEST (Zocular Eyelid System Treatment) procedure show significant improvements in tear breakup time (TBUT) and OSDI scores, along with reductions in inflammatory markers like MMP-9 and Demodex mite counts.

Therapeutic areas: OphthalmologyDermatology
Modalities: Botanical-based formulationPolysaccharidesMicellesDevice
Industry: Biotech

Drug pipeline

3 assets

natural extract gel

Preclinical

2 more assets in the full pipeline.

Partnerships

NovaBay Pharmaceuticals

Beyond the preview

Go deeper on Zocular.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Zocular.